Calcium Polycarbophil in the Management of Fecal Incontinence

Background: Few clinical studies have assessed the efficacy of calcium polycarbophil that is currently recommended as an ideal and initial bulk-forming agent in patients with fecal incontinence.

Aims: The aim of this study was to evaluate the short-term outcomes of calcium polycarbophil administration to patients with fecal incontinence due to a range of etiologies.

Study Design: This was a retrospective review of a single-institution experience.

Methodology: In total, 223 patients treated with calcium polycarbophil were enrolled. Efficacy measures included changes in the Cleveland Clinic Incontinence Score and the Bristol Stool Form Scale.

Results: Of the 223 patients who were enrolled, 195 were available for final analysis. Among the 195 patients, 15 (7.7%) experienced side effects; the most common side effects were constipation and hard stools. One month after the start of treatment, the mean Cleveland Clinic Incontinence Score decreased significantly compared with baseline (11.2±4.0 vs. 5.7±5.0, P = < .001). The mean stool consistency decreased significantly, with patients reporting more formed stools by the Bristol Stool Form Scale at 1 month than at baseline (4.4±1.5 vs. 3.9±1.1, P = < .001).

Conclusions: Our findings suggest that monotherapy with calcium polycarbophil appears to be a safe and beneficial approach in the management of fecal incontinence.